Active Pharmaceutical Ingredients Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030

CHAPTER 1. Industry Overview of Active Pharmaceutical Ingredient Market

1.1. Definition and Scope

1.1.1. Definition of Active Pharmaceutical Ingredient

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Active Pharmaceutical Ingredient Market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Active Pharmaceutical Ingredient Market By Type of Synthesis

1.2.3. Active Pharmaceutical Ingredient Market By Type of Manufacturer

1.2.4. Active Pharmaceutical Ingredient Market By Type

1.2.5. Active Pharmaceutical Ingredient Market By Application

1.2.6. Active Pharmaceutical Ingredient Market By Region

CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Source

2.2.1. Secondary Sources

2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restraint 1

3.2.2. Restraint 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Active Pharmaceutical Ingredient Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Active Pharmaceutical Ingredient Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Cost Structure Analysis

3.8.1. Price Trend of Key Raw Materials

3.8.2. Raw Material Suppliers

3.8.3. Proportion of Manufacturing Cost Structure

3.8.3.1. Raw Material

3.8.3.2. Labor Cost

3.8.3.3. Manufacturing Expense

3.9. Regulatory Compliance

3.10. Competitive Landscape, 2021

3.10.1. Player Positioning Analysis

3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Manufacturing Plant Analysis

4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2021

4.2. R&D Status of Major Manufacturers in 2021

CHAPTER 5. Active Pharmaceutical Ingredient Market By Type of Synthesis

5.1. Introduction

5.2. Active Pharmaceutical Ingredient Revenue By Type of Synthesis

5.2.1. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast, By Type of Synthesis, 2018-2030

5.2.2. Biotech

5.2.2.1. Biotech Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.2.2. Monoclonal Antibodies

5.2.2.2.1. Monoclonal Antibodies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.2.3. Recombinant Proteins

5.2.2.3.1. Recombinant Proteins Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.2.4. Vaccines

5.2.2.4.1. Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

5.2.3. Vaccines

5.2.3.1. Vaccines Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 6. Active Pharmaceutical Ingredient Market By Type of Manufacturer

6.1. Introduction

6.2. Active Pharmaceutical Ingredient Revenue By Type of Manufacturer

6.2.1. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast, By Type of Manufacturer, 2018-2030

6.2.2. Captive APIs

6.2.2.1. Captive APIs Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

6.2.3. Merchant APIs

6.2.3.1. Merchant APIs Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 7. Active Pharmaceutical Ingredient Market By Type

7.1. Introduction

7.2. Active Pharmaceutical Ingredient Revenue By Type

7.2.1. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast, By Type, 2018-2030

7.2.2. Innovative APIs

7.2.2.1. Innovative APIs Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

7.2.3. Generic APIs

7.2.3.1. Generic APIs Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 8. Active Pharmaceutical Ingredient Market By Application

8.1. Introduction

8.2. Active Pharmaceutical Ingredient Revenue By Application

8.2.1. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast, By Application, 2018-2030

8.2.2. Cardiology

8.2.2.1. Cardiology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.3. Orthopedic

8.2.3.1. Orthopedic Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.4. Oncology

8.2.4.1. Oncology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.5. Endocrinology

8.2.5.1. Endocrinology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.6. Pulmonology

8.2.6.1. Pulmonology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.7. Gastroenterology

8.2.7.1. Gastroenterology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.8. CNS & Neurology

8.2.8.1. CNS & Neurology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.9. Nephrology

8.2.9.1. Nephrology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.10. Ophthalmology

8.2.10.1. Ophthalmology Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

8.2.11. Others

8.2.11.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030

CHAPTER 9. North America Active Pharmaceutical Ingredient Market By Country 

9.1. North America Active Pharmaceutical Ingredient Market Overview

9.2. U.S.

9.2.1. U.S. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

9.2.2. U.S. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

9.2.3. U.S. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

9.2.4. U.S. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

9.3. Canada

9.3.1. Canada Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

9.3.2. Canada Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

9.3.3. Canada Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

9.3.4. Canada Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

9.4. North America PEST Analysis

CHAPTER 10. Europe Active Pharmaceutical Ingredient Market By Country

10.1. Europe Active Pharmaceutical Ingredient Market Overview

10.2. U.K.

10.2.1. U.K. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

10.2.2. U.K. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

10.2.3. U.K. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

10.2.4. U.K. Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

10.3. Germany

10.3.1. Germany Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

10.3.2. Germany Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

10.3.3. Germany Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

10.3.4. Germany Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

10.4. France

10.4.1. France Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

10.4.2. France Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

10.4.3. France Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

10.4.4. France Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

10.5. Spain

10.5.1. Spain Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

10.5.2. Spain Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

10.5.3. Spain Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

10.5.4. Spain Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

10.6. Rest of Europe

10.6.1. Rest of Europe Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

10.6.2. Rest of Europe Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

10.6.3. Rest of Europe Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

10.6.4. Rest of Europe Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

10.7. Europe PEST Analysis

CHAPTER 11. Asia Pacific Active Pharmaceutical Ingredient Market By Country

11.1. Asia Pacific Active Pharmaceutical Ingredient Market Overview

11.2. China

11.2.1. China Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

11.2.2. China Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

11.2.3. China Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

11.2.4. China Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

11.3. Japan

11.3.1. Japan Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

11.3.2. Japan Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

11.3.3. Japan Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

11.3.4. Japan Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

11.4. India

11.4.1. India Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

11.4.2. India Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

11.4.3. India Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

11.4.4. India Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

11.5. Australia

11.5.1. Australia Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

11.5.2. Australia Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

11.5.3. Australia Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

11.5.4. Australia Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

11.6. South Korea

11.6.1. South Korea Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

11.6.2. South Korea Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

11.6.3. South Korea Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

11.6.4. South Korea Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

11.7. Rest of Asia-Pacific

11.7.1. Rest of Asia-Pacific Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

11.7.2. Rest of Asia-Pacific Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

11.7.3. Rest of Asia-Pacific Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

11.7.4. Rest of Asia-Pacific Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

11.8. Asia Pacific PEST Analysis

CHAPTER 12. Latin America Active Pharmaceutical Ingredient Market By Country

12.1. Latin America Active Pharmaceutical Ingredient Market Overview

12.2. Brazil

12.2.1. Brazil Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

12.2.2. Brazil Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

12.2.3. Brazil Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

12.2.4. Brazil Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

12.3. Mexico

12.3.1. Mexico Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

12.3.2. Mexico Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

12.3.3. Mexico Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

12.3.4. Mexico Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

12.4. Rest of Latin America

12.4.1. Rest of Latin America Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

12.4.2. Rest of Latin America Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

12.4.3. Rest of Latin America Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

12.4.4. Rest of Latin America Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

12.5. Latin America PEST Analysis

CHAPTER 13. Middle East & Africa Active Pharmaceutical Ingredient Market By Country 

13.1. Middle East & Africa Active Pharmaceutical Ingredient Market Overview

13.2. GCC

13.2.1. GCC Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

13.2.2. GCC Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

13.2.3. GCC Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

13.2.4. GCC Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

13.3. South Africa

13.3.1. South Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

13.3.2. South Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

13.3.3. South Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

13.3.4. South Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

13.4. Rest of Middle East & Africa

13.4.1. Rest of Middle East & Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Synthesis, 2018-2030

13.4.2. Rest of Middle East & Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type of Manufacturer, 2018-2030

13.4.3. Rest of Middle East & Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Type, 2018-2030

13.4.4. Rest of Middle East & Africa Active Pharmaceutical Ingredient Revenue (USD Billion) and Forecast By Application, 2018-2030

13.5. Middle East & Africa PEST Analysis

CHAPTER 14. Player Analysis Of Active Pharmaceutical Ingredient Market

14.1. Active Pharmaceutical Ingredient Market Company Share Analysis

14.2. Competition Matrix

14.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment

14.2.2. New Product Launches and Product Enhancements

14.2.3. Mergers And Acquisition In Global Active Pharmaceutical Ingredient Market

14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 15. Company Profile

15.1. AbbVie Inc.

15.1.1. Company Snapshot

15.1.2. Business Overview

15.1.3. Financial Overview

15.1.3.1. Revenue (USD Billion), 2021

15.1.3.2. AbbVie Inc. 2021 Active Pharmaceutical Ingredient Business Regional Distribution

15.1.4. Product/Service and Specification

15.1.5. Recent Developments & Business Strategy

15.2. Merck & Co., Inc.

15.3. Boehringer Ingelheim International GmbH

15.4. Teva Pharmaceutical Industries Ltd

15.5. Cipla, Inc.

15.6. Albemarle Corporation

15.7. Bristol-Myers Squibb Company

15.8. Sun Pharmaceutical Industries Ltd.

15.9. Mylan N.V.

15.10. Aurobindo Pharma

15.11. Dr. Reddy’s Laboratories Ltd.